<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p73" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_73{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_73{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_73{left:141px;bottom:1104px;letter-spacing:-0.01px;}
#t4_73{left:248px;bottom:1104px;letter-spacing:0.25px;}
#t5_73{left:143px;bottom:1047px;letter-spacing:-0.29px;}
#t6_73{left:250px;bottom:1067px;letter-spacing:-0.01px;}
#t7_73{left:250px;bottom:1047px;letter-spacing:-0.01px;}
#t8_73{left:248px;bottom:992px;letter-spacing:-0.04px;}
#t9_73{left:238px;bottom:933px;letter-spacing:-0.01px;}
#ta_73{left:238px;bottom:913px;letter-spacing:-0.01px;}
#tb_73{left:238px;bottom:894px;letter-spacing:-0.01px;}
#tc_73{left:626px;bottom:894px;letter-spacing:-0.01px;}
#td_73{left:238px;bottom:874px;letter-spacing:-0.01px;}
#te_73{left:238px;bottom:855px;letter-spacing:-0.01px;}
#tf_73{left:238px;bottom:835px;letter-spacing:-0.01px;}
#tg_73{left:238px;bottom:816px;letter-spacing:-0.01px;}
#th_73{left:238px;bottom:797px;letter-spacing:-0.01px;}
#ti_73{left:238px;bottom:777px;letter-spacing:-0.01px;}
#tj_73{left:238px;bottom:758px;letter-spacing:-0.01px;}
#tk_73{left:238px;bottom:738px;letter-spacing:-0.01px;}
#tl_73{left:238px;bottom:719px;letter-spacing:-0.01px;}
#tm_73{left:238px;bottom:699px;letter-spacing:-0.01px;}
#tn_73{left:238px;bottom:680px;letter-spacing:-0.01px;}
#to_73{left:238px;bottom:661px;letter-spacing:-0.01px;}
#tp_73{left:238px;bottom:548px;letter-spacing:-0.01px;}
#tq_73{left:238px;bottom:529px;letter-spacing:-0.01px;}
#tr_73{left:238px;bottom:509px;letter-spacing:-0.01px;}
#ts_73{left:238px;bottom:490px;letter-spacing:-0.01px;}
#tt_73{left:238px;bottom:470px;letter-spacing:-0.01px;}
#tu_73{left:238px;bottom:436px;letter-spacing:-0.01px;}
#tv_73{left:238px;bottom:416px;letter-spacing:-0.01px;}
#tw_73{left:238px;bottom:362px;letter-spacing:-0.01px;}
#tx_73{left:238px;bottom:343px;letter-spacing:-0.01px;}
#ty_73{left:238px;bottom:323px;letter-spacing:-0.01px;}
#tz_73{left:238px;bottom:304px;letter-spacing:-0.01px;}
#t10_73{left:238px;bottom:284px;letter-spacing:-0.01px;}
#t11_73{left:238px;bottom:265px;letter-spacing:-0.01px;}
#t12_73{left:238px;bottom:245px;letter-spacing:-0.01px;}
#t13_73{left:238px;bottom:226px;letter-spacing:-0.01px;}
#t14_73{left:238px;bottom:207px;letter-spacing:-0.01px;}
#t15_73{left:238px;bottom:187px;letter-spacing:-0.01px;}
#t16_73{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_73{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_73{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_73{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_73{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_73{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_73{font-size:13px;font-family:NotoSans-Regular_7j-_1;color:#000;}
.s6_73{font-size:11px;font-family:NotoSans-Regular_7j-_1;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts73" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

@font-face {
	font-family: NotoSans-Regular_7j-_1;
	src: url("fonts/NotoSans-Regular_7j-_1.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg73Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg73" style="-webkit-user-select: none;"><object width="908" height="1286" data="73/73.svg" type="image/svg+xml" id="pdf73" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_73" class="t s0_73">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_73" class="t s1_73">73 </span>
<span id="t3_73" class="t s2_73">7.41. </span><span id="t4_73" class="t s0_73">Consensus-based recommendation </span>
<span id="t5_73" class="t s3_73">EEC </span>
<span id="t6_73" class="t s2_73">Postoperative radiotherapy should be started as soon as possible after wound healing </span>
<span id="t7_73" class="t s2_73">and should be completed within a maximum period of 11 weeks after surgery. </span>
<span id="t8_73" class="t s4_73">Strong consensus: 100% </span>
<span id="t9_73" class="t s2_73">If primary laryngectomy is attempted, the possible need for postoperative radio- or </span>
<span id="ta_73" class="t s2_73">radiochemotherapy must be taken into account. Although randomized studies on the effect of </span>
<span id="tb_73" class="t s2_73">postoperative radiotherapy compared to “no adjuvant therapy” </span><span id="tc_73" class="t s5_73">are lacking, the results of </span>
<span id="td_73" class="t s5_73">cohort studies and prospective databases for patients with &gt;pN1 lymph node involvement, </span>
<span id="te_73" class="t s5_73">extracapsular tumor growth in the lymph nodes (ECE) or with tumor-free surgical resection </span>
<span id="tf_73" class="t s5_73">margins &lt;5mm showed such a clear superiority of adjuvant radiotherapy that randomized </span>
<span id="tg_73" class="t s5_73">studies were not carried out [238-241]. In patients with a particularly high risk of relapse (ECE </span>
<span id="th_73" class="t s5_73">in the lymph nodes or with tumor-free surgical resection margins &lt;5mm), randomized studies </span>
<span id="ti_73" class="t s5_73">were able to show a clear advantage in terms of locoregional tumor control and overall </span>
<span id="tj_73" class="t s5_73">survival for simultaneous radiochemotherapy compared to radiotherapy alone [235, 242, 243]. </span>
<span id="tk_73" class="t s5_73">In contrast, no randomized study has shown an advantage for adjuvant chemotherapy alone </span>
<span id="tl_73" class="t s5_73">[185]. If postoperative radiotherapy or radiochemotherapy is indicated, it should be started 3-5 </span>
<span id="tm_73" class="t s5_73">weeks after surgery. Several retrospective studies have independently shown that significantly </span>
<span id="tn_73" class="t s5_73">more locoregional relapses are observed with longer intervals until the start of radiotherapy </span>
<span id="to_73" class="t s2_73">[244-246]. </span>
<span id="tp_73" class="t s5_73">Postoperative radio- or chemoradiotherapy should be administered in pT3 carcinomas and </span>
<span id="tq_73" class="t s5_73">pT4a carcinomas, in carcinomas with narrow or positive resection margins, perineural </span>
<span id="tr_73" class="t s5_73">invasion, vascular invasion (lymphatic vessel invasion and/or venous invasion), in more than </span>
<span id="ts_73" class="t s5_73">one involved lymph node, and in an involved lymph node with extracapsular tumor growth </span>
<span id="tt_73" class="t s2_73">[238-241]. </span>
<span id="tu_73" class="t s5_73">Postoperative radiotherapy should be started as early as possible after wound healing </span>
<span id="tv_73" class="t s5_73">and should be completed within a maximum of 11 weeks after surgery [244-246]. </span>
<span id="tw_73" class="t s5_73">Since the total doses required for adjuvant radiotherapy are not significantly lower than those </span>
<span id="tx_73" class="t s5_73">of primary radiotherapy (66 Gy vs. 70 Gy), the acute and late side effects of adjuvant therapy are </span>
<span id="ty_73" class="t s5_73">only slightly lower than those of primary radiotherapy or chemoradiotherapy. Approximately </span>
<span id="tz_73" class="t s5_73">35% of patients treated adjuvantly, regardless of whether radiotherapy alone or simultaneous </span>
<span id="t10_73" class="t s5_73">chemoradiotherapy was used, experienced one or more grade III/IV late side effects [234]. A </span>
<span id="t11_73" class="t s5_73">significant proportion of these side effects also include swallowing problems, particularly with </span>
<span id="t12_73" class="t s5_73">accelerated radiotherapy and simultaneous chemoradiotherapy [240]. The median dose to the </span>
<span id="t13_73" class="t s5_73">pharyngeal constrictor muscles has been shown to be an important predictor of persistent </span>
<span id="t14_73" class="t s5_73">swallowing disorders, with a dose reduction of 10% to the pharyngeal constrictors in the range </span>
<span id="t15_73" class="t s5_73">of 50 -70 Gy increasing the probability </span>
<span id="t16_73" class="t s6_73">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
